A thyroid medicine recall is drawing attention after the US Food and Drug Administration gave the affected product its most serious recall classification.
The recall involves one lot of Thyroid Tablets, USP 30 mg, which is sold by Vitruvias Therapeutics. The company voluntarily had recalled the tablets in August after testing found they could be “superpotent,” which means that they may contain more thyroid hormone than intended. Then the FDA classified the recall as Class I on September 22.
